8Porte DJ.Banting Lecture 1990.β-cells in type Ⅱ diabetes mellitus.Diabetes,1991,40:166—180.
9Pratley RE,Weyer C.The role of impaired early insulin secretion in the pathogenesis of type Ⅱ diabetes mellitus.Diabetologia,2001,44:929—945.
10McGuire EAH, Helderman J H, Tobin JD, et al. Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol, 1976, 41:565-573.
6Kirkman MS, Shankar RR, Shankar S, et al. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the early diabetes intervention program [J]. Diabetes Care, 2006,29 (9) : 2095- 2101.
7Goke B,Lubben G,Batcs PC. Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose[J]. Exp Clin Endocrinol Diabetes, 2004,112 (2) : 115- 117.
8Bermudez-Pirela VJ, Cano C, Medina MT, et al. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR) and beta-cell function ( HOMA ( beta-cell ) without hyperinsulinemia in patients with type 2 diabetes mellitus[J]. Am J Ther,2007,14(2):194-202.
9Choi SH, Zhao ZS, Lee Y J, et al. The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats [J]. Diabetes Metab Res Rev,2007,23(5) :411-418.
10Kim HJ,Kang ES, Kim DJ, et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus[J]. Clin Endocrinol, 2007,66 (2) : 282-289.